Biogen Idec (BIIB)
Add to Watchlists Create an AlertBiogen Idec Liabilities:
2.826B for March 31, 2013Biogen Idec Historical Liabilities Data
Pro Data ExportThere is no data for the selected date range.
| Data for this Date Range | |
|---|---|
| March 31, 2013 | 2.826B |
| Dec. 31, 2012 | 3.169B |
| Sept. 30, 2012 | 2.971B |
| June 30, 2012 | 2.894B |
| March 31, 2012 | 2.808B |
| Dec. 31, 2011 | 2.624B |
| Sept. 30, 2011 | 2.573B |
| June 30, 2011 | 2.645B |
| March 31, 2011 | 2.689B |
| Dec. 31, 2010 | 2.696B |
| Sept. 30, 2010 | 2.363B |
| June 30, 2010 | 2.331B |
| March 31, 2010 | 2.308B |
| Dec. 31, 2009 | 2.330B |
| Sept. 30, 2009 | 2.462B |
| June 30, 2009 | 2.565B |
| March 31, 2009 | 2.588B |
| Dec. 31, 2008 | 2.673B |
About Total Liabilities
Liabilities are obligations of a company arising from past transactions or events which are expected to reduce assets when they are settled.
Note : This is a simple term, but fairly complex topic. A company's balance sheet is made up of three components : Assets, Liabilities, and Shareholder's Equity. Assets are equivalent to the sum of liabilities and shareholder's equity.
Let's say a company sells computers. The assets would be the machinery, the plant, the inventory, etc. the company. However, the value of these assets belong to who funded the company. Is the company backed by obligations/debt (loans from a bank, inventory from a supplier)? or ... The founder / common public's (shareholder's equity)? Most likely, a combination of both.
Simply, liabilities are the part of a company's assets that it has yet to repay back.
Learn More
BIIB Liabilities Benchmarks
| Companies | |
|---|---|
| Elan | 931.50M |
| Novartis | 53.98B |
| Celgene Corporation | 5.898B |
BIIB Liabilities Rankings
| Overall |
45th percentile 4377 of 8005 |
| Sector |
15th percentile 581 of 686 in Healthcare |
| Industry |
10th percentile 223 of 248 in Biotechnology |
BIIB Liabilities Range, Past 5 Years
| Minimum | 2.308B | Mar 2010 |
| Maximum | 3.169B | Dec 2012 |
| Average | 2.640B |
